Home
What’s New in the Guidelines?
Introduction
COVID-19
Laboratory Testing
Tests for Initial Assessment and Follow-up
Plasma HIV-1 RNA (Viral Load) and CD4 Count Monitoring
Drug-Resistance Testing
Co-receptor Tropism Assays
HLA-B* 5701 Screening
Treatment as Prevention
Initiation of Antiretroviral Therapy
What to Start
Management of the Treatment-Experienced Patient
Virologic Failure
Poor CD4 Recovery
Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression
Special Patient Populations
Acute and Recent (Early) HIV Infection
Adolescents and Young Adults with HIV
HIV-2 Infection
HIV and the Older Patient
Substance Use Disorders and HIV
Transgender People with HIV
Women with HIV
Considerations for Antiretroviral Use in Patients with Coinfections
Hepatitis B Virus/HIV Coinfection
Hepatitis C Virus/HIV Coinfection
Mycobacterium Tuberculosis Disease with HIV Coinfection
Limitations to Treatment Safety and Efficacy
Adherence to the Continuum of Care
Adverse Effects of Antiretroviral Agents
Cost Considerations and Antiretroviral Therapy
Drug-Drug Interactions
Overview
PI Drug Interactions
NNRTI Drug Interactions
NRTI Drug Interactions
INSTI Drug Interactions
CCR5 Antagonist Drug Interactions
Interactions Between PIs and NNRTIs
Interactions Between INSTI & NNRTI or PI
Drug Characteristics Tables
NRTIs
NNRTIs
PIs
INSTI
Fusion Inhibitor
CCR5 Antagonist
CD4 Post-Attachment Inhibitor
ARV Dosing for Renal or Hepatic Insufficiency
Bookmarks
Contact Us
Antiretroviral Guidelines
US DHHS Guidelines with Australian commentary
Bookmarks
No Favorites
×
Home
What’s New in the Guidelines?
Introduction
COVID-19
Laboratory Testing
← Back
Tests for Initial Assessment and Follow-up
Plasma HIV-1 RNA (Viral Load) and CD4 Count Monitoring
Drug-Resistance Testing
Co-receptor Tropism Assays
HLA-B* 5701 Screening
Treatment as Prevention
Initiation of Antiretroviral Therapy
What to Start
Management of the Treatment-Experienced Patient
← Back
Virologic Failure
Poor CD4 Recovery
Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression
Special Patient Populations
← Back
Acute and Recent (Early) HIV Infection
Adolescents and Young Adults with HIV
HIV-2 Infection
HIV and the Older Patient
Substance Use Disorders and HIV
Transgender People with HIV
Women with HIV
Considerations for Antiretroviral Use in Patients with Coinfections
← Back
Hepatitis B Virus/HIV Coinfection
Hepatitis C Virus/HIV Coinfection
Mycobacterium Tuberculosis Disease with HIV Coinfection
Limitations to Treatment Safety and Efficacy
← Back
Adherence to the Continuum of Care
Adverse Effects of Antiretroviral Agents
Cost Considerations and Antiretroviral Therapy
Drug-Drug Interactions
← Back
Overview
PI Drug Interactions
NNRTI Drug Interactions
NRTI Drug Interactions
INSTI Drug Interactions
CCR5 Antagonist Drug Interactions
Interactions Between PIs and NNRTIs
Interactions Between INSTI & NNRTI or PI
Drug Characteristics Tables
← Back
NRTIs
NNRTIs
PIs
INSTI
Fusion Inhibitor
CCR5 Antagonist
CD4 Post-Attachment Inhibitor
ARV Dosing for Renal or Hepatic Insufficiency
Bookmarks
Contact Us